GH Research PLC
NASDAQ:GHRSBiotechnology
Healthcare
$18.25 -0.18%
-$0.04 today
- Market cap
- $1.25B
- Beta
- 1.31
- P/E (TTM)
- -23.8
- EPS (TTM)
- -$0.91
52W Low $11.32High $25.94
Volume 0.46M
Average 0.23M
GHRS EBITDA Margin
EBITDA as a percentage of revenue.
No reported EBITDA Margin figures are available to summarize.
EBITDA Margin history
Percent of revenue · from the income statement
No EBITDA Margin data reported for this period type.
EBITDA Margin vs competitors
How GHRS compares with its peers on the latest reported figures
GHRS Competitors Peer median
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -590.7% | — | — |
| FY2025 | — | — | — | |
DFTXDefinium Therapeutics, Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding GHRS) | -590.7% | — | — | |
Competitors are the stored peer set for GHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 335K |
| Gross Profit | 0 | 0 | 0 | 0 | (335K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 8.55M | 20.48M | 29.82M | 35.02M | 38.73M |
| Selling, General & Admin | 6.54M | 10.06M | 11.12M | 15M | 21.61M |
| Operating Expenses | 15.1M | 30.55M | 41.22M | 50.31M | 60.34M |
| Depreciation & Amortization | 19K | 47K | 315K | 315K | 335K |
| EBITDA | (9.17M) | (22.41M) | (35.21M) | (38.6M) | (47.46M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (15.1M) | (30.55M) | (41.22M) | (50.31M) | (60.68M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 9 | 858K | 1.89M | 2.63M | 2.63M |
| Interest Expense | 9K | — | 723K | 717K | 463K |
| Other Income / Expenses | 5.9M | 8.1M | 5.64M | 11.35M | 12.42M |
| Income Before Tax | (9.2M) | (22.46M) | (35.59M) | (38.96M) | (48.26M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (9.2M) | (22.46M) | (35.59M) | (38.96M) | (48.26M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.18) | (0.14) | (0.68) | (0.75) | (0.79) |
| EPS (Diluted) | (0.18) | (0.14) | (0.68) | (0.75) | (0.79) |
| Weighted Avg Shares | 52.02M | 52.02M | 52.02M | 52.03M | 61.04M |
| Weighted Avg Shares (Diluted) | 52.02M | 52.02M | 52.02M | 52.03M | 61.04M |
GH Research PLC
NASDAQ:GHRS
Intrinsic Alpha fair value
Locked
Current Price
$18.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.